Pro/con debate: Is intensive insulin therapy targeting tight blood glucose control of benefit in critically ill patients? by Merz, Tobias M & Finfer, Simon
Page 1 of 6
(page number not for citation purposes)
Available online http://ccforum.com/content/12/2/212
Abstract
You have decided to develop a protocol for insulin therapy in your
intensive care unit (ICU). You wonder about the merit of using
intensive insulin therapy (IIT) to maintain tight blood glucose
control in your patients.
Pro: Intensive insulin therapy targeting tight
blood glucose control is of benefit in critically
ill patients
Hyperglycaemia is a common accompaniment of acute
illness. In published trials insulin treatment was required in
more than 98% of ICU patients in whom the goal was to
maintain normoglycaemia [1-3]. The hyperglycaemia is thought
to result from a number of processes; elevated levels of
cortisol, epinephrine, norepinephrine and glucagon increase
gluconeogenesis [4-8] and glycogenolysis [9] whilst insulin
resistance leads to a decrease in insulin-stimulated uptake of
glucose in heart and adipose tissue. In addition, exercise
induced uptake of glucose in skeletal muscle is absent in
immobilized critically ill patients [10,11]. Hyperglycaemia may
cause harm by direct toxicity and through increased
intracellular oxidative stress due to higher mitochondrial
peroxide production [12,13]. The clinical consequence of
hyperglycaemia appears to be an increase in morbidity and
mortality in a variety of clinical settings, including hetero-
geneous populations of critically ill patients [14]. In trauma
patients hyperglycaemia is associated with higher mortality
and an increased rate of infectious complications [15] as well
as with worse neurological outcome in the subset of patients
with traumatic brain injury [16]. In patients with sepsis and
haematological malignancy, hyperglycaemia at hospital
admission predicts higher mortality [17,18]. Hyperglycaemia
has also been associated with higher mortality and poor
functional recovery in non-diabetic stroke patients [19], and
with increased risk of in-hospital mortality, congestive heart
failure and cardiogenic shock after myocardial infarction [20].
In summary, hyperglycaemia is common in critically ill patients
and its occurrence is clearly associated with a worse
outcome; thus, it is natural to ask whether hyperglycaemia is
simply a marker of illness severity, or is hyperglycaemia itself
harmful, in which case does normalizing blood glucose
improve patients’ outcomes?
The evidence that short-term treatment of hyperglycaemia is
beneficial in acute illness is consistent across a number of
populations of patients. Insulin treatment targeting a lower
blood glucose concentration significantly reduces long term
mortality following myocardial infarction [21], and lowers the
risk of cardiovascular disease and cardiovascular events in
patients with type I diabetes [22]. A meta-analysis evaluating
35 randomized controlled trials (RCTs) of insulin therapy in
critically ill hospitalized patients found a beneficial effect of
insulin therapy on mortality; the benefit was limited to trials in
which insulin was administered with the goal of achieving a
particular blood glucose target [23].
Although the majority of studies included in the meta-analysis
were conducted in patients with coronary artery disease, the
single largest study was the surgical ICU (SICU) study by
Van den Berghe and colleagues [1]. In this study, the
investigators randomly assigned mechanically ventilated
SICU patients to either intensive insulin therapy (IIT; blood
glucose target 4.4 to 6.1 mmol/l) or conventional treatment
(blood glucose target 10.0 to 11.1 mmol/l). The study was
stopped after inclusion of 1,548 patients when a planned
interim analysis indicated a significant reduction in mortality in
patients assigned to IIT. Patients assigned to IIT had lower
ICU mortality (4.6% versus 8.0%, adjusted p < 0.04) and in-
hospital mortality (7.2% versus 10.9%, p = 0.01). The bene-
ficial effect of IIT occurred in patients who remained in the
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ICU for more than five days (ICU mortality 10.6% versus
20.2%, p = 0.01); the number of deaths in the first five days
of intensive care was similar in both groups. Van den Berghe
and colleagues repeated their study in medical ICU (MICU)
patients expected to be in the ICU for three days or more [2].
They enrolled 1,200 patients, of whom 767 were treated in
the ICU for three days or longer. Overall, in-hospital mortality
was lower in patients assigned to IIT (37.3% versus 40.0%),
but the difference was not statistically significant (p = 0.33).
In patients who were treated in the ICU for 3 days or more, in-
hospital mortality was reduced in those assigned to IIT
(43.0% versus 52.5%, p = 0.009). In addition to its impact on
survival, Van den Berghe and colleagues’ studies suggest IIT
is associated with beneficial effects on a variety of indicators
of morbidity; benefits included a decrease in incidence of
critical illness polyneuropathy [24,25] and acute renal failure
[2], and reduced duration of mechanical ventilation. In Van
den Berghe and colleagues’ SICU study there was also a
reduction in blood stream infections and reduced use of renal
replacement therapy and blood transfusion [1].
Following publication of Van den Berghe and colleagues’ first
study, IIT was adopted in some ICUs and improved outcomes
were reported in comparison with historical controls [26,27].
IIT is associated with increased ICU resource use for
administration of insulin and close monitoring of blood
glucose levels [28]. However, a post hoc analysis of health
care resource utilization derived from the data from Van den
Berghe and colleagues’ SICU study reported an overall
reduction in medical costs [29], and similar cost savings
compared to historical controls were reported by Krinsley and
Jones [30]. In both studies the cost savings occurred due to
a shorter ICU stay and reduced expenditure on mechanical
ventilation.
Two European multi-centre RCTs of IIT have been initiated
but then stopped because of rates of hypoglycaemia
considered unacceptable by their data monitoring commit-
tees [3,31]. The Volume Substitution and Insulin Therapy in
Severe Sepsis (VISEP) study [3], which recruited 537
participants in 18 hospitals in Germany, is the only trial report
to be published in full to date. Early stopping of the trial
resulted in only 247 patients being treated with IIT across 18
centres, an average of less than 14 patients per centre. As IIT
is a complex treatment to administer, it is possible that the
limited number of patients treated at each site was
responsible for, or at least contributed to, the lack of treat-
ment effect; this phenomenon has been observed in at least
one prior trial in patients with severe sepsis [32].
In conclusion, the available data from two RCTs and large
observational studies suggest that maintaining strict
normoglycaemia by means of IIT reduces mortality and
morbidity in both MICU and SICU patients. The beneficial
effect seems to be even more pronounced in the most
severely ill patients requiring prolonged intensive care. The
additional costs for the more complex therapy and intensive
monitoring are more than offset by the reduced overall
resource consumption.
Con: Intensive insulin therapy targeting tight
blood glucose control is of benefit in critically
ill patients
It seems clear that hyperglycaemia is a common accompani-
ment of acute illness and that its occurrence and severity are
associated with worse outcomes. Maintaining normo-
glycaemia through IIT significantly reduced mortality in Van
den Berghe and colleagues’ SICU trial [1] and reduced
morbidity in their MICU trial [2], and their results have
subsequently been replicated in studies using historical
controls [26,27]. Furthermore, control of blood glucose has
proven beneficial in other populations of acutely ill patients
[23]. Whilst to some such data are sufficient to advocate IIT
as a standard of care for critically ill adults [26], it is more
prudent to critically evaluate the strength of the evidence
before subjecting critically ill patients to such treatment.
The evidence in favour of IIT in ICU patients comes from two
RCTs conducted sequentially in the SICUs and MICUs at a
University Hospital in Leuven [1,2]. The results, particularly in
the SICU population, where the relative risk of in-hospital
death was reduced by 33.9%, seem compelling but, as noted
by the authors, the patients studied in that trial were
ventilated surgical patients admitted to the ICU after
predominantly cardiac surgery and these results cannot be
extrapolated to other ICU patient groups. Whether the results
can be extrapolated to SICU patients worldwide has been
questioned by a number of commentators [33,34]; concerns
raised include an apparently high mortality rate in the control
group, unusual concomitant treatment in the form of a high
dose intravenous glucose regimen and that the remarkable
reduction in mortality may itself call the trial results into
question [35]. The in-hospital mortality of 10.9% in the
conventional treatment group seems higher than expected for
surgical ICU patients with a median Acute Physiology and
Chronic Health Evaluation (APACHE) II score of 9. An ICU
mortality rate of 5.1% for cardiac surgery patients also
appears high as reported hospital mortality rates range from
0.9% to 3.6% [36-38]. In support of this contention, Egi and
colleagues [39] identified patients from the databases of four
hospitals in Australia who most closely matched the control
group patients in Van den Berghe and colleagues’ SICU
study; they reported an in-hospital mortality rate of 3.8%,
which was substantially lower than both the conventional and
IIT groups in Van den Berghe and colleagues’ study.
In both Van den Berghe and colleagues’ studies, the patients
received predominantly parenteral nutrition; the average daily
intravenous glucose load was 160 ± 66 g in the conven-
tionally treated patients and 161 ± 64 g in patients treated
with IIT [40] - in an inception cohort study in Australia and
New Zealand the median daily intravenous glucose load wasPage 3 of 6
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12.2 g [41]. In the pooled data analysis of Van den Berghe
and colleagues’ studies, 86% of all surgical and medical
patients received predominately parenteral calories; only
39% received any enteral nutrition during their ICU stay. The
percentage of total calories administered by the enteral route
was 17.7% for the conventional group and 14.6% for the IIT
group [40]. Neither the use of high-dose intravenous glucose
nor the early institution of parenteral nutrition is recom-
mended in current practice guidelines [42-44]. The partici-
pants in the VISEP trial received over 40% of their
kilocalories by the enteral route and, given the potentially
complex interplay between glucose administration, glycaemic
control and outcome, it may be unsafe to extrapolate Van den
Berghe and colleagues’ findings to patients receiving more
conventional feeding regimens.
Enrolment in Van den Berghe and colleagues’ SICU study
was stopped for efficacy after 1,548 of the planned 2,500
patients had been recruited. Trials that are stopped early may
systematically overestimate treatment effects and where the
number of accrued outcome events is small, the over-
estimation may be very large [45,46]. Where mortality is the
primary outcome it may be wise to continue a study until 200
to 400 deaths have occurred and the p-value for the
difference in mortality is less than 0.001 [46].
Van den Berghe and colleagues’ MICU study [2] included a
more heterogeneous population of patients, with a higher
severity of illness represented by a mean APACHE II score of
23. Although there was a reduction in mortality with IIT, the
difference did not reach the traditionally accepted level of
statistical significance in the intention-to-treat analysis. The
intention-to-treat analysis is always the most relevant result
for any randomized controlled trial as it represents the effect
of the treatment in all the patients studied [47], and the likely
outcome if others use the treatment in similar populations of
patients. Although the authors reported reduced mortality in
patients who stayed in the ICU for three days or more, these
patients could not be identified at the time treatment was
started and so clinicians can not know to which of their
patients this result might apply.
In both Van den Berghe and colleagues’ studies hypo-
glycaemia occurred significantly more often in the IIT group
(5.1 versus 0.8% in the surgical patients; 18.7 versus 3.1%
in medical patients). MICU patients might be at higher risk for
occurrence of hypoglycaemia due to the higher incidence of
sepsis, and the necessity for renal replacement therapy and
inotropic support, all of which have been identified as risk
factors in the context of IIT [48].
In contrast to Van den Berghe and colleagues’ findings, two
multi-centre RCTs have stopped early after interim analyses
found that IIT increased the risk of severe hypoglycaemia
without any evidence of improved survival [3,31]. The VISEP
study was conducted in 18 academic tertiary hospitals in
Germany using treatment protocols based on Van den
Berghe and colleagues’ studies [3]. The study stopped after
inclusion of 488 patients because of an increased incidence
of severe hypoglycaemia with IIT (17.0 versus 4.1%) and no
mortality benefit. The Glucontrol study examined the impact
of IIT versus conventional treatment in 21 ICUs in 19
hospitals in 7 European countries [31]. The study was
stopped after recruiting 1,101 of the planned 3,500 patients;
severe hypoglycaemia occurred in 9.8% of the IIT group
compared to 2.7% in the conventional arm, and ICU mortality
did not differ significantly between the two groups (16.7%
versus 15.2%) [31]. A further RCT, which recruited 523
patients in a mixed MICU and SICU in Saudi Arabia has also
reported an increased risk of severe hypoglycaemia but no
mortality benefit [49].
Although a number of authors have reported decreased
mortality after adopting IIT [26,27], these observations
provide, at best, very weak evidence in favour of IIT. As noted
by Stewart and colleagues [27], changes in treatment
protocols do not occur in isolation; in their surgical trauma
ICU, institution of IIT was accompanied by a reduction in
mortality, but during the period of study they also imple-
mented a ventilator management protocol, a sedation
protocol, and introduced a pneumonia prevention bundle. It is
impossible to say which (if any) of these interventions was
responsible for reduced mortality and the same criticism
applies to all studies using historical controls.
In conclusion, critical appraisal of the high-quality evidence
must conclude that IIT is an unproven treatment that should
not be adopted widely until benefit is confirmed in large, high-
quality, multi-centre RCTs.
Authors’ opinion: What is the merit of using
intensive insulin therapy to maintain tight
blood glucose control in our patients?
Our clinical practice is in a multidisciplinary adult ICU that
admits medical patients and patients following general
surgery, trauma, burns, spinal injuries, cardiothoracic surgery
and neurosurgery; is IIT indicated in any or all of these patient
groups? Given the bewildering proliferation of literature on
the subject, selective or biased reviews of the evidence can
advance convincing arguments both for and against the use
of IIT. In our view, the best evidence for or against any
treatment comes from large, high-quality RCTs; we agree
with Collins and MacMahon [50] that the reliable assessment
of effects of treatment on major outcomes requires studies
that guarantee strict control of bias through proper
randomisation and appropriate analysis and interpretation
(with no undue emphasis placed on specific parts of the
evidence), and strict control of random error by reporting (in
the present context) large numbers of deaths. Additionally,
the argument for using any treatment is strengthened if
supported by trials that have run to their planned conclusion
and if clinical trials report consistent results.
Available online http://ccforum.com/content/12/2/212If we apply these principles, should we use IIT? To date, only
one high-quality RCT supports the use of IIT (Figure 1); as
that trial was stopped early and reported only 140 deaths, we
can not exclude the possibility of significant random error
[45,50]. The results have not been confirmed by subsequent
multi-centre studies, but both multi-centre studies reported to
date were stopped early and neither reported more than 200
deaths [3,31]. The one large published study that has run to
completion [40], and which reported 442 deaths, did not find
a significant treatment effect and so we would consider the
evidence in favour of IIT to be equivocal at best. An ongoing
international multi-centre study (The NICE-SUGAR study)
that plans to recruit 6,100 patients and expects to report
between 1,500 and 1,800 deaths may provide strong
evidence either for or against the use of IIT [33].
Even if we conclude that current evidence is not strong
enough to advocate targeting normoglycaemia, the concept
of IIT remains intuitively appealing and doing nothing is not an
option. Glucose control appears beneficial in other popula-
tions of patients [21,23], although some of the trials have
been small [21]. As in many areas of intensive care practice,
the choice of a target range for blood glucose is a matter of
balancing potential benefit against potential risk, and
considering the resource implications of the treatment
against a background of equivocal or incomplete evidence.
Use of IIT has consistently resulted in an increased risk of
severe hypoglycaemia. Two case-control studies that examined
the association between hypoglycaemia and death reached
different conclusions; one concluded that hypoglycaemia was
independently associated with death [51], whilst the other
concluded it was not [52]. Given these conflicting results,
and the limited reliability of case-control studies, we conclude
that whilst there is no consistent evidence that rapidly
corrected hypoglycaemia is harmful, this possibility can not
currently be ruled out. The other significant negative factor is
that IIT is labour intensive and may require as much as two
hours of nursing time per patient per day [28].
The balance between benefit and harm of a specific blood
glucose target range depends on a variety of factors,
including case mix, baseline morbidity and mortality as well as
the characteristics of the individual ICU, such as availability of
staff and laboratory equipment [39]. Until the balance of risks
and benefits is better defined, we consider universal
treatment guidelines or recommendations to target normo-
glycaemia to be premature. Each ICU should define a blood
glucose range that can be achieved without causing a
significant increase in severe hypoglycaemia and that fits
within the constraints of their nursing and economic
resources; for our multi-disciplinary ICU, and pending the
results of the NICE-SUGAR study, the upper limit of this
range is currently 8 to 10 mmol/l (140 to 180 mg/dl).
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